1. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance–United States, 2005.
MMWR Surveill Summ. 2006;55(5):1–108.
[PubMed: 16760893]
2. Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15–44 years of age, United States, 2002. Adv Data. 2005(362):1–55.
3. Stone N, Hatherall B, Ingham R, McEachran J. Oral sex and condom use among young people in the United Kingdom.
Perspect Sex Reprod Health. 2006;38(1):6–12.
[PubMed: 16554266]
4. So DW, Wong FY, DeLeon JM. Sex, HIV risks, and substance use among Asian American college students.
AIDS Educ Prev. 2005;17(5):457–468.
[PubMed: 16255641]
5. Weinstock H, Berman S, Cates W, Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000.
Perspect Sex Reprod Health. 2004;36(1):6–10.
[PubMed: 14982671]
6. Hatherall B, Ingham R, Stone N, McEachran J. How, not just if, condoms are used: the timing of condom application and removal during vaginal sex among young people in England.
Sex Transm Infect. 2007;83(1):68–70.
[PubMed: 16901916]
7. Shrier LA, Goodman E, Emans SJ. Partner condom use among adolescent girls with sexually transmitted diseases.
J Adolesc Health. 1999;24(5):357–361.
[PubMed: 10331842]
8. Diclemente RJ, Wingood GM, Sionean C, et al. Association of adolescents’ history of sexually transmitted disease (STD) and their current high-risk behavior and STD status: a case for intensifying clinic-based prevention efforts.
Sex Transm Infect. 2002;29(9):503–509.
[PubMed: 12218840]
9. Finer LB, Darroch JE, Singh S. Sexual partnership patterns as a behavioral risk factor for sexually transmitted diseases.
Fam Plann Perspect. 1999;31(5):228–236.
[PubMed: 10723647]
10. Kelley SS, Borawski EA, Flocke SA, Keen KJ. The role of sequential and concurrent sexual relationships in the risk of sexually transmitted diseases among adolescents.
J Adolesc Health. 2003;32(4):296–305.
[PubMed: 12667734]
11. Millstein SG, Moscicki AB. Sexually-transmitted disease in female adolescents: effects of psychosocial factors and high risk behaviors.
J Adolesc Health. 1995;17(2):83–90.
[PubMed: 7495830]
12. Ethier KA, Kershaw T, Niccolai L, Lewis JB, Ickovics JR. Adolescent women underestimate their susceptibility to sexually transmitted infections.
Sex Transm Infect. 2003;79(5):408–411.
[PubMed: 14573838]
13. Klein JD, McNulty M, Flatau CN. Adolescents’ access to care: teenagers’ self-reported use of services and perceived access to confidential care.
Arch Pediatr Adolesc Med. 1998;152(7):676–682.
[PubMed: 9667540]
14. Klein JD, Wilson KM, McNulty M, Kapphahn C, Collins KS. Access to medical care for adolescents: results from the 1997 commonwealth fund survey of the health of adolescent girls.
J Adolesc Health. 1999;25(2):120–130.
[PubMed: 10447039]
15. Boonstra H. Comprehensive approach needed to combat sexually transmitted infections among youth. The Guttmacher Report on Public Policy, March 2004:3–4,13.
16. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2005. Atlanta, GA: Department of Health and Human Services; 2006.
17. Shafer M, Countouriotis A. Chlamydia trachomatis. In: Neinstein L, ed.Adolescent Health Care: A Practical Guide. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:1138–1160.
18. Cohen MS, Sparling PF. Mucosal infection with
Neisseria gonorrhoeae. Bacterial adaptation and mucosal defenses.
J Clin Invest. 1992;89(6):1699–1705.
[PubMed: 1601981]
19. Chacko MR, Lovchik JC. Chlamydia trachomatis infection in sexually active adolescents: prevalence and risk factors.
Pediatrics. 1984;73(6):836–840.
[PubMed: 6547226]
20. Shrier LA. Sexually transmitted diseases in adolescents: biologic, cognitive, psychologic, behavioral, and social issues.
Adolesc Med Clin. 2004;15(2):215–234.
[PubMed: 15449842]
21. Sheeder J, Stevens-Simon C, Lezotte D, Glazner J, Scott S. Cervicitis: to treat or not to treat? The role of patient preferences and decision analysis.
J Adolesc Health. 2006;39(6):887–892.
[PubMed: 17116520]
22. Karaer A, Avsar FA, Batioglu S. Risk factors for ectopic pregnancy: a case-control study.
Aust N Z J Obstet Gynaecol. 2006;46(6):521–527.
[PubMed: 17116058]
23. Gray-Swain MR, Peipert JF. Pelvic inflammatory disease in adolescents.
Curr Opin Obstet Gynecol. 2006;18(5):503–510.
[PubMed: 16932044]
24. Simpson T, Oh MK. Urethritis and cervicitis in adolescents.
Adolesc Med Clin. 2004;15(2):253–271.
[PubMed: 15449844]
25. Johnson RE, Newhall WJ, Papp JR, et al. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections–2002. MMWR Recomm Rep. 2002;51(RR-15):1–38; quiz CE1–4.
26. Gaydos CA. Nucleic acid amplification tests for gonorrhea and chlamydia: practice and applications.
Infect Dis Clin North Am. 2005;19(2):367–386, ix.
[PubMed: 15963877]
27. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR. 2006;55(No. RR-11):1–94.
28. Screening for chlamydial infection: recommendations and rationale. Am J Prev Med. 2001;20(3 suppl):90–94.
29. Screening for gonorrhea: recommendation statement. Ann Fam Med. 2005;3(3):263–267.
30. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2005. Commun Dis Intell. 2006;30(4):430–433.
31. Martin IM, Hoffmann S, Ison CA. European surveillance of sexually transmitted infections (ESSTI): the first combined antimicrobial susceptibility data for
Neisseria gonorrhoeae in Western Europe.
J Antimicrob Chemother. 2006;58(3):587–593.
[PubMed: 16816397]
32. Iverson CJ, Wang SA, Lee MV, et al. Fluoroquinolone resistance among
Neisseria gonorrhoeae isolates in Hawaii, 1990–2000: role of foreign importation and increasing endemic spread.
Sex Transm Dis. 2004;31(12):702–708.
[PubMed: 15608583]
33. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men–United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR Morb Mortal Wkly Rep. 2004;53(16):335–338.
34. CDC. Sexually Transmitted Disease Sureveillance 2004 Supplement: Gonococcal Isolate Surveillance Project (GISP) Annual Report 2004. Atlanta, GA: U.S. Department of Health and Human Services, 2005.
35. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: Fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. 2007;56(14):332–336.
36. Discontinuation of cefixime tablets–United States. MMWR Morb Mortal Wkly Rep. 2002;51(46):1052.
37. Lyss SB, Kamb ML, Peterman TA, et al. Chlamydia trachomatis among patients infected with and treated for
Neisseria gonorrhoeae in sexually transmitted disease clinics in the United States.
Ann Intern Med. 2003;139(3): 178–185.
[PubMed: 12899585]
38. Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States.
JAMA. 2004;291(18):2229–2236.
[PubMed: 15138245]
39. Sena AC, Miller WC, Hobbs MM, et al.
Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention.
Clin Infect Dis. 2007;44(1):13–22.
[PubMed: 17143809]
40. Miller WC, Swygard H, Hobbs MM, et al. The prevalence of trichomoniasis in young adults in the United States.
Sex Transm Dis. 2005;32(10):593–598.
[PubMed: 16205299]
41. Schwebke JR, Hook EW, III. High rates of
Trichomonas vaginalis among men attending a sexually transmitted diseases clinic: implications for screening and urethritis management.
J Infect Dis. 2003;188(3):465–468.
[PubMed: 12870131]
42. Van Der Pol B, Williams JA, Orr DP, Batteiger BE, Fortenberry JD. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis. 2005;192(12): 2039–2044.
43. Wendel KA, Workowski KA. Trichomoniasis: challenges to appropriate management. Clin Infect Dis. 2007;44 (suppl 3):S123-S129.
44. Schwebke JR, Burgess D. Trichomoniasis.
Clin Microbiol Rev. 2004;17(4):794–803.
[PubMed: 15489349]
45. Syed TS, Braverman PK. Vaginitis in adolescents.
Adolesc Med Clin. 2004;15(2):235–251.
[PubMed: 15449843]
46. Haward M, Shafer M. Vaginitis and cervicitis. Adolescent Health Care: A Practical Guide. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2002:1011–1028.
47. Hardy PH, Hardy JB, Nell EE, Graham DA, Spence MR, Rosenbaum RC. Prevalence of six sexually transmitted disease agents among pregnant inner-city adolescents and pregnancy outcome.
Lancet. 1984;2(8398):333–337.
[PubMed: 6146874]
48. Cotch MF, Pastorek JG, II, Nugent RP, et al.
Trichomonas vaginalis associated with low birth weight and preterm delivery. The vaginal infections and prematurity study group.
Sex Trans Dis. 1997;24(6):353–360.
[PubMed: 9243743]
49. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study.
AIDS (London, England). 1993;7(1):95–102.
[PubMed: 8442924]
50. Sorvillo F, Kerndt P.
Trichomonas vaginalis and amplification of HIV-1 transmission.
Lancet. 1998;351(9097):213–214.
[PubMed: 9449891]
51. Minkoff H, Grunebaum AN, Schwarz RH, et al. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy.
Am J Obstetr Gynecol. 1984;150(8):965–972.
[PubMed: 6391179]
52. Joyner JL, Douglas JM, Jr., Ragsdale S, Foster M, Judson FN. Comparative prevalence of infection with
Trichomonas vaginalis among men attending a sexually transmitted diseases clinic.
Sex Trans Dis. 2000;27(4):236–240.
[PubMed: 10782747]
53. Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of
Trichomonas vaginalis.
Clin Microbiol Rev. 1998;11(2):300–317.
[PubMed: 9564565]
54. Freeto JP, Jay MS. “What's really going on down there?” A practical approach to the adolescent who has gynecologic complaints.
Pediatr Clin North Am. 2006;53(3):529–545, viii.
[PubMed: 16716795]
55. Hatcher R, Nelson, AL. Combined hormonal contraceptive methods. In: Hatcher R, Trussell J, Stewart F, et al. ed.Contraceptive Technology. 18th ed. New York, NY: Ardent Media, Inc; 2004:391–460.
56. Holland-Hall CM, Wiesenfeld HC, Murray PJ. Self-collected vaginal swabs for the detection of multiple sexually transmitted infections in adolescent girls.
J Pediatr Adolesc Gynecol. 2002;15(5):307–313.
[PubMed: 12547662]
57. Smith K, Harrington K, Wingood G, Oh MK, Hook EW, III, DiClemente RJ. Self-obtained vaginal swabs for diagnosis of treatable sexually transmitted diseases in adolescent girls.
Arch Pediatr Adolesc Med. 2001;155(6):676–679.
[PubMed: 11386956]
58. Sobel JD. What's new in bacterial vaginosis and trichomoniasis?
Infect Dis Clin North Am. 2005;19(2):387–406.
[PubMed: 15963878]
59. Wiese W, Patel SR, Patel SC, Ohl CA, Estrada CA. A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis.
Am J Med. 2000;108(4): 301–308.
[PubMed: 11014723]
60. Briselden AM, Hillier SL. Evaluation of affirm VP microbial identification test for gardnerella vaginalis and
Trichomonas vaginalis.
J Clin Microbiol. 1994;32(1):148–152.
[PubMed: 8126171]
61. DeMeo LR, Draper DL, McGregor JA, et al. Evaluation of a deoxyribonucleic acid probe for the detection of
Trichomonas vaginalis in vaginal secretions.
Am J Obstetr Gynecol. 1996;174(4):1339–1342.
[PubMed: 8623867]
62. Huppert JS, Batteiger BE, Braslins P, et al. Use of an immunochromatographic assay for rapid detection of
Trichomonas vaginalis in vaginal specimens.
J Clin Microbiol. 2005;43(2):684–687.
[PubMed: 15695664]
63. Patel SR, Wiese W, Patel SC, Ohl C, Byrd JC, Estrada CA. Systematic review of diagnostic tests for vaginal trichomoniasis.
Infect Dis Obstetr Gynecol. 2000;8(5–6):248–257.
[PubMed: 11220487]
64. Ohlemeyer CL, Hornberger LL, Lynch DA, Swierkosz EM. Diagnosis of
Trichomonas vaginalis in adolescent females: InPouch TV culture versus wet-mount microscopy.
J Adolesc Health. 1998;22(3):205–208.
[PubMed: 9502007]
65. Wendel KA, Erbelding EJ, Gaydos CA, Rompalo AM.
Trichomonas vaginalis polymerase chain reaction compared with standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoniasis.
Clin Infect Dis. 2002;35(5):576–580.
[PubMed: 12173132]
66. Caliendo AM, Jordan JA, Green AM, Ingersoll J, Diclemente RJ, Wingood GM. Real-time PCR improves detection of
Trichomonas vaginalis infection compared with culture using self-collected vaginal swabs.
Infect Dis Obstetr Gynecol. 2005;13(3):145–150.
[PubMed: 16126499]
68. Ahmed AM, Madkan V, Tyring SK. Human papillomaviruses and genital disease.
Dermatol Clin. 2006;24(2):157–165, vi.
[PubMed: 16677964]
69. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men.
Lancet Infect Dis. 2006;6(1):21–31.
[PubMed: 16377531]
70. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States.
JAMA. 2007;297(8):813–819.
[PubMed: 17327523]
71. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females.
JAMA. 2001;285(23):2995–3002.
[PubMed: 11410098]
72. Nicholls PK, Moore PF, Anderson DM, et al. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes.
Virology. 2001;283(1):31–39.
[PubMed: 11312659]
73. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer.
N Engl J Med. 2003;348(6):518–527.
[PubMed: 12571259]
74. Mansur C. Human papillomaviruses. In: Tyring SK, ed.Mucocutaneous Manifestations of Viral Diseases. New York, NY: Marcel Dekker, Inc; 2002:247–294.
75. Bartholomew DA. Human papillomavirus infection in adolescents: a rational approach.
Adolesc Med Clin. 2004;15(3):569–595.
[PubMed: 15625994]
76. ACOG Committee Opinion. Evaluation and management of abnormal cervical cytology and histology in the adolescent. Number 330, April 2006. Obstet Gynecol. 2006;107(4): 963–968.
78. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1–24.
79. Speck LM, Tyring SK. Vaccines for the prevention of human papillomavirus infections.
Skin Therapy Lett. 2006;11(6):1–3.
[PubMed: 16912836]